ESR1 and breast carcinoma: It will be interesting to retrospectively evaluate MYC status using clinicogenomic data from the BOLERO-2 trial or other clinical trials that evaluated everolimus-based therapies for ER+/HER2− breast cancer in different first-line settings (Rozenblit et al., 2021; Dhakal et al., 2018).